Literature DB >> 20163025

[A case of lung adenocarcinoma exhibiting Garcin syndrome].

Yasuko Aida1, Akira Igarashi, Sumito Inoue, Shuichi Abe, Yoko Shibata, Isao Kubota.   

Abstract

We report a rare case of lung adenocarcinoma exhibiting Garcin syndrome due to skull base metastasis. A diagnosis of lung adenocarcinoma and intraperitoneal lymph node metastases was given to a 50-year-old man after pathological examination of a superclavicular lymph node biopsy. After systemic chemotherapy with cisplatin plus docetaxel, he had left hearing loss and vertigo. Since auditory nerve damage might occur due to cisplatin, the chemotherapy regimen was changed. However, facial paralysis occurred and his auditory nerve disorder progressed to deafness. He was diagnosed with Garcin syndrome due to the skull base and spinal cord metastases by brain and spine MRI, and cytological examination of the spinal fluid. After intrathecal administration of methotrexate and cranial irradiation, the progression of facial paralysis and auditory nerve disorder were halted. It is important to consider Garcin syndrome as a possible complication in lung cancer patients who have central nervous system symptoms.

Entities:  

Mesh:

Year:  2010        PMID: 20163025

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  3 in total

1.  Garcin syndrome in a case of acquired immunodeficiency syndrome.

Authors:  Ilad Alavi Darazam; Mohammad Mahdi Rabiei; Hooman Bahrami-Motlagh; Omid Moradi; Farid Javandoust Gharehbagh; Farahnaz Bidari Zerehpoosh; Firouze Hatami; Nader Akbari Dilmaghani; Maziar Shojaei; Legha Lotfollahi
Journal:  Clin Case Rep       Date:  2022-10-17

Review 2.  Disorders of the lower cranial nerves.

Authors:  Josef Finsterer; Wolfgang Grisold
Journal:  J Neurosci Rural Pract       Date:  2015 Jul-Sep

3.  Garcin syndrome caused by sphenoid bone metastasis of lung cancer: a case study.

Authors:  Satoshi Fukai; Naoyuki Okabe; Hayato Mine; Hironori Takagi; Hiroyuki Suzuki
Journal:  World J Surg Oncol       Date:  2018-03-06       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.